Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DocMorris AGXSWX:DOCM -5.94%65 Future 3-5Y EPS without NRI Growth Rate is 37.33 as of Aug. 01, 2026. GuruFocus rates XSWX:DOCM with a GF Score™ of 65/100 and a GF Value™ of CHF10.70 (Fairly Valued). The stock has 8 warning signs investors should review. Among 197 Healthcare Providers & Services companies, DocMorris AG ranks better than 81.22% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, DocMorris AG's Future 3-5Y EPS without NRI Growth Rate is 37.33.
DocMorris AG (XSWX:DOCM) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
DocMorris AG Future 3-5Y EPS without NRI Growth Rate Related Terms
DocMorris AG Future 3-5Y EPS without NRI Growth Rate Competitor Comparison
For the Pharmaceutical Retailers subindustry, DocMorris AG's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocMorris AG Future 3-5Y EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocMorris AG's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where DocMorris AG's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 37.33 mean?
DocMorris AG (XSWX:DOCM) has a Future 3-5Y EPS without NRI Growth Rate of 37.33 as of Aug. 01, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for DocMorris AG and its competitors. According to the industry distribution chart, DocMorris AG ranks #37 out of 197 companies in the Healthcare Providers & Services industry, placing it in the top 18.8%.
Is DocMorris AG's Future 3-5Y EPS without NRI Growth Rate too high?
DocMorris AG's current Future 3-5Y EPS without NRI Growth Rate is 37.33. The Healthcare Providers & Services industry median Future 3-5Y EPS without NRI Growth Rate is 16.40. DocMorris AG's value of 37.33 is 127.6% above this industry median. Based on the distribution chart, DocMorris AG ranks #37 out of 197 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DocMorris AG has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's Future 3-5Y EPS without NRI Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DocMorris AG ranks #37 out of 197 companies for Future 3-5Y EPS without NRI Growth Rate. This places DocMorris AG in the top 19% of its industry — outperforming the majority of peers. The industry median Future 3-5Y EPS without NRI Growth Rate is 16.40. DocMorris AG's value of 37.33 is 127.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median Future 3-5Y EPS without NRI Growth Rate among Healthcare Providers & Services companies is 16.40, based on 197 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocMorris AG's current Future 3-5Y EPS without NRI Growth Rate of 37.33 is 127.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for DocMorris AG and its competitors. For the Healthcare Providers & Services industry, the median Future 3-5Y EPS without NRI Growth Rate is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocMorris AG's current Future 3-5Y EPS without NRI Growth Rate is 37.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Fairly Valued. The stock's GF Value™ is CHF10.70, compared to a current price of CHF9.82 — trading 8.2% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 37.33 and 127.6% above the Healthcare Providers & Services industry median of 16.40. DocMorris AG's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current Future 3-5Y EPS without NRI Growth Rate is 37.33 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?
Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued.
The current stock price of CHF9.82 is trading 8.2% below its estimated GF Value™ of CHF10.70.
GuruFocus considers DocMorris AG to be Fairly Valued.
Key valuation signals for XSWX:DOCM:
Future 3-5Y EPS without NRI Growth Rate: 37.33
GF Value™: CHF10.70 vs. price of CHF9.82 (8.2% below fair value)
Industry Position: 127.6% above the Healthcare Providers & Services median (#37 of 197)
No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
65GF Score
Get the complete analysis for XSWX:DOCM
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DOCM has been successfully added to your 
